TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. FDA
TRACT Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company
NEWS
- Sep 1, 2019
Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells
SCIENTIFIC REPORTS, A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor Kidney Transplants” April...
- Jun 25, 2016
TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™
TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment...
- Jun 24, 2016
Results of Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in Kidney Transplant Recipients
Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients Download the...
- May 12, 2016
TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial
TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient’s Immune Cells to Prevent Organ Rejection CHICAGO -...
- Feb 17, 2016
American Transplant Congress June 12, 2016
Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in de novo living donor kidney transplant recipients. Download the full...
- Aug 16, 2015
TRACT Therapeutics, Inc. Completes Phase I Safety Trial
TRACT Therapeutics, Inc. Completes Phase I Safety Trial Using a Patient’s Immune Cells to Prevent Organ Rejection Safety Data Presented...
- Mar 4, 2015
International Society for Cellular Therapy
International Society for Cellular Therapy, Miltenyi Biotec Corporate Symposium, May 27, 2015, Las Vegas, NV Ann LeFever, PhD to present...
- Feb 26, 2015
TRACT Therapeutics, Inc. in White City News
“A kidney transplant that lasts for life. It’s the ultimate goal. But the drugs that keep a donor organ going also pose the greatest...